Table III.
OS and PFS rates at different levels of B7-H3 expression and CD163+ TAM infiltration in patients with UCB.
| A, All patients (n=134) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| OS, % (±SE) | PFS, % (±SE) | ||||||||
| Feature | n | 1 year | 5 years | 10 years | P-value | 1 year | 5 years | 10 years | P-value |
| B7-H3 expression | 0.002 | 0.020 | |||||||
| High | 93 | 96.8 (1.8) | 23.9 (4.9) | 13.6 (6.6) | 68.5 (4.8) | 22.1 (5.6) | 11.0 (8.3) | ||
| Low | 41 | 97.6 (2.4) | 40.2 (7.8) | 27.8 (8.2) | 90.1 (4.7) | 34.1 (7.8) | 25.9 (8.0) | ||
| CD163+ TAM infiltration | 0.074 | 0.090 | |||||||
| High | 59 | 98.3 (1.7) | 22.0 (5.8) | 16.5 (6.4) | 65.5 (6.2) | 23.7 (5.6) | 15.8 (7.5) | ||
| Low | 75 | 97.3 (1.9) | 35.3 (5.8) | 22.1 (6.1) | 82.6 (4.4) | 32.2 (5.7) | 22.8 (6.2) | ||
| B, Patients with muscle-invasive bladder cancer (n=115) | |||||||||
| OS, % (±SE) | PFS, % (±SE) | ||||||||
| Feature | n | 1 year | 5 years | 10 years | P-value | 1 year | 5 years | 10 years | P-value |
| B7-H3 expression | <0.001 | <0.001 | |||||||
| High | 79 | 98.7 (1.3) | 14.9 (4.5) | 0 (0.0) | 71.8 (5.1) | 16.8 (4.6) | 0 (0.0) | ||
| Low | 36 | 100 (0.0) | 58.1 (8.7) | 47.7 (9.9) | 94.4 (3.8) | 52.0 (9.2) | 43.4 (11.0) | ||
| CD163+ TAM infiltration | 0.022 | 0.017 | |||||||
| High | 54 | 100 (0.0) | 15.9 (5.5) | 8.0 (6.3) | 73.6 (6.1) | 14.9 (5.3) | 0 (0.0) | ||
| Low | 61 | 98.4 (1.6) | 43.2 (6.7) | 26.4 (7.6) | 81.9 (4.9) | 35.8 (6.8) | 25.1 (8.1) | ||
OS, overall survival; PFS, progression-free survival; SE, standard error; CD163, cluster of differentiation; TAM, tumor-associated macrophage; UCB, urinary carcinoma of the bladder.